J. M. Vose

1.8k total citations
34 papers, 1.2k citations indexed

About

J. M. Vose is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, J. M. Vose has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pathology and Forensic Medicine, 20 papers in Genetics and 14 papers in Oncology. Recurrent topics in J. M. Vose's work include Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Lung Cancer Treatments and Mutations (10 papers). J. M. Vose is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Lung Cancer Treatments and Mutations (10 papers). J. M. Vose collaborates with scholars based in United States, Netherlands and France. J. M. Vose's co-authors include J. O. Armitage, Anne Kessinger, J R Anderson, Philip J. Bierman, P. J. Bierman, Jamés O. Armitage, Elizabeth Reed, P. Coccia, Bruce G. Gordon and Izidore S. Lossos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. M. Vose

33 papers receiving 1.2k citations

Peers

Countries citing papers authored by J. M. Vose

Since Specialization

Citations

This map shows the geographic impact of J. M. Vose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. M. Vose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. M. Vose more than expected).

Fields of papers citing papers by J. M. Vose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. M. Vose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. M. Vose. The network helps show where J. M. Vose may publish in the future.

Co-authorship network of co-authors of J. M. Vose

This figure shows the co-authorship network connecting the top 25 collaborators of J. M. Vose. A scholar is included among the top collaborators of J. M. Vose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. M. Vose. J. M. Vose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program 2012 ·Bone Marrow Transplantation ·Paul Shaughnessy, Joseph P. Uberti, Steven M. Devine, (unknown), J. M. Vose, Ivana N. Micallef, Eric D. Jacobsen, John M. McCarty, Patrick J. Stiff, Andrew Artz, Edward D. Ball, R.B. Berryman, Michael J. Dugan, Robin Joyce, Frank J. Hsu, David G. Johns, Peter A. McSweeney	29
2	Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma 2010 ·CA A Cancer Journal for Clinicians ·(unknown), (unknown), J. M. Vose	174
3	Does a negative post-therapy PET obviate the need for any further follow-up imaging in patients with nonbulky early-stage Hodgkin's lymphoma (HL)? 2010 ·Journal of Clinical Oncology ·Andrea Gallamini, A. Biggi, Stéphane Chauvie, Antonio Bianchi, (unknown), Frédéric Di Fiore, Roberto Sorasio, J. M. Vose, (unknown), Malik E. Juweid	1
4	Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin’s lymphoma 2003 ·Annals of Oncology ·J. M. Vose, Vesna Šneller	22
5	Oligonucleotide Enhanced Cytotoxicity of Idarubicin for Lymphoma Cells 2001 ·Leukemia & lymphoma ·John Sharp, Michael Bishop, Bryan L. Copple, Timothy C. Greiner, Patrick L. Iversen, John D. Jackson, S. K. Joshi, (unknown), (unknown), Anitha Rao, J. M. Vose	5
6	Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma. 1998 ·Journal of Clinical Oncology ·J. M. Vose, Philip J. Bierman, James C. Lynch, DD Weisenburger, Anne Kessinger, Wing C. Chan, Timothy C. Greiner, J. O. Armitage	10
7	Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade nonhodgkin lymphoma: Effect on failure-free survival 1998 ·Anne Kessinger, P. J. Bierman, Mary Kathryn Cowles, J R Anderson, J. O. Armitage, Michael Bishop, J. M. Vose	3
8	Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy. 1996 ·Journal of Clinical Oncology ·J. M. Vose, J Anderson, P. J. Bierman, F R Appelbaum, J R Anderson, Leslie Garrison, M. E. Lebsack, Jamés O. Armitage	9
9	Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma. 1996 ·Journal of Clinical Oncology ·J. M. Vose, P. J. Bierman, J R Anderson, Katherine Harrison, Glenn V. Dalrymple, (unknown), Anne Kessinger, Jamés O. Armitage	49
10	Hodgkin's disease following solid organ transplantation 1996 ·Annals of Oncology ·Philip J. Bierman, J. M. Vose, Alan N. Langnas, (unknown), (unknown), Bassam N. Smir, Timothy C. Greiner	42
11	High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy 1996 ·Annals of Oncology ·Philip J. Bierman, J R Anderson, Michele Freeman, J. M. Vose, Anne Kessinger, Michael Bishop, J. O. Armitage	61
12	Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. 1996 ·PubMed ·J. M. Vose	9
13	Clinical applications of hematopoietic growth factors. 1995 ·Journal of Clinical Oncology ·J. M. Vose, J. O. Armitage	91
14	Bone Marrow Transplantation for Hodgkin's Disease and Lymphoma 1993 ·Annual Review of Medicine ·J. M. Vose, J O Armitage	1
15	Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. 1993 ·Journal of Clinical Oncology ·J. M. Vose, Elizabeth Reed, (unknown), J R Anderson, Philip J. Bierman, Anne Kessinger, Jorge A. Spinolo, Jamés O. Armitage	86
16	High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. 1993 ·Journal of Clinical Oncology ·J. M. Vose, J R Anderson, Anne Kessinger, P. J. Bierman, P. Coccia, Elizabeth Reed, Bruce G. Gordon, J. O. Armitage	182
17	Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. 1993 ·Journal of Clinical Oncology ·J R Anderson, J. M. Vose, Philip J. Bierman, (unknown), Warren G. Sanger, J Pierson, M. Bast, Jamés O. Armitage	52
18	Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. 1993 ·Journal of Clinical Oncology ·P. J. Bierman, J. M. Vose, Peter K. Leichner, Syed M. Quadri, J. O. Armitage, J Klein, (unknown), K. A. Dicke, H. M. Vriesendorp	37
19	Salvage therapy for patients with non-Hodgkin's lymphoma 1990 ·Jamés O. Armitage, J. M. Vose, P. J. Bierman	2
20	Correlation of Secondary Cytogenetic Abnormalities With Histologic Appearance in Non-Hodgkin's Lymphomas Bearing t(14;18)(q32;q21) 1988 ·JNCI Journal of the National Cancer Institute ·Jamés O. Armitage, Warren G. Sanger, D D Weisenburger, Douglas S. Harrington, J Linder, Philip J. Bierman, J. M. Vose, David T. Purtilo	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact